Skip to content

Vivani Medical VANI Grants Available To Offset Future Operating Expenses

Grants Available To Offset Future Operating Expenses at other companies

OS Therapies logo
OS TherapiesOSTX
$50K
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$6.2M+265%
American Battery Technology Company logo
American Battery Technology CompanyABAT
$200K0.0%
SHA
SharonAI Holdings, Inc. Class A Common StockSHAZ
$891.48K
Blink Charging Co. logo
Blink Charging Co.BLNK
$758K
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$6.34M

Other financials

Income statement

See full
Revenue-
Gross profit$130.0K
Operating income-$6.8M-4.0%
Net income-$6.8M-7.6%
EPS (diluted)-$0.08+27.3%

Balance sheet

See full
Cash & equivalents$19.0M+57.7%
Total debt$18.3M-3.5%
Total equity$19.1M+64.2%
Total assets$42.4M+19.5%

Cash flow

See full
Operating cash flow-$6.2M-20.0%
CapEx$3.0K-40.0%
Free cash flow-$6.2M-19.9%

Valuation

See full
Market cap$106.93M+40.0%
Enterprise value$106.17M+19.3%

Profitability

See full
Gross margin36.3%
Operating margin-1,004.9%
Net margin-994.1%
FCF margin-832.3%

Returns & leverage

See full
Return on equity-176.4%+175pp
Debt / equity-0.7×
Current ratio3.2×+0.8×

Where this comes from

Reported directly by Vivani Medical in its filing.

Tagged under the XBRL concept vani:GrantsAvailableToOffsetFutureOperatingExpenses.

The official record: Vivani Medical’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's grants available to offset future operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vivani Medical's grants available to offset future operating expenses?
Vivani Medical (VANI) reported grants available to offset future operating expenses of $0 in Q4 2024.
What does grants available to offset future operating expenses mean?
This represents the remaining balance of non-dilutive funding or research grants awarded to the company that have not yet been recognized as revenue or applied against expenses. It serves as a liquidity indicator for preclinical-stage companies, highlighting the extent to which external funding can subsidize ongoing research and development activities without requiring additional equity financing.